Sequential Treatment Use in Clinical Practice for U.S. Patients with Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (R/M HNSCC)

D. Zheng,C.M. Black,G.M. Hair,B. Bidadi,N. Lerman,L. Ai,A. Zion,L. Zou,W. Gao,G.J. Hanna

DOI: https://doi.org/10.1016/j.ijrobp.2024.01.079

IF: 8.013

2024-04-01

International Journal of Radiation Oncology*Biology*Physics

Abstract:Purpose/Objective(s) Since the approval of pembrolizumab monotherapy in the platinum-refractory setting for R/M HNSCC in 2016 and the subsequent approval of pembrolizumab alone or in combination with chemotherapy in first-line (1L) in 2019, pembrolizumab-based therapy has become a standard of care. To better understand current real-world practice patterns, this study assessed the use of sequential systemic treatment from 1L to 2L for patients with R/M HNSCC. Materials/Methods A retrospective cohort study was conducted using the Flatiron Health Advanced Head and Neck database. The study cohort included adult patients with R/M HNSCC who initiated 1L systemic therapy between 07/01/19 and 12/31/22 with follow-up through 06/30/23. Patients were excluded if they received platinum treatment ≤6 months prior to 1L therapy, had head and neck cancer subtypes other than SCC of the hypopharynx, larynx, oropharynx, or oral cavity, or were treated in a clinical trial. Results A total of 1879 patients were included. Median age was 67 years (IQR: 60, 74). Most were male (77.1%) and had an Eastern Cooperative Oncology Group (ECOG) performance status score of 0-1 (71.7%). HPV-positivity was reported in 70.8% (602/850) of tested oropharyngeal cancers. Table 1 shows the 1L treatment utilization with over half patients (58.9%) received pembrolizumab with or without chemotherapy in 1L. Patients who received 1L pembrolizumab monotherapy had the oldest age (median: 70 years), the highest proportion of ECOG≥2 (21.2%) and CPS≥1 (85.5%). Approximately 39.5% received a 2L therapy, 47.9% had no subsequent line of therapy at the end of follow-up, and 12.5% died during or after 1L therapy. Cetuximab-based regimens were the most used 2L therapy (25.1%), followed by pembrolizumab alone (23.1%) and platinum-based chemotherapy (14.5%). Of 231 patients starting pembrolizumab alone in 1L who later received subsequent treatment, 14 (6.1%) had platinum and 5-fluorouracil added, 41 (17.7%) had other chemotherapy added, and 27 (11.7%) were retreated with pembrolizumab alone. Conclusion Pembrolizumab alone or in combination with chemotherapy were the most widely used in 1L for R/M HNSCC; over 40% of patients received other 1L therapies. Patients receiving pembrolizumab alone in 1L had different characteristics favoring older, more frail patients. Understanding the sequential use of immunotherapy is important to inform optimal management of patients with R/M HNSCC.

oncology,radiology, nuclear medicine & medical imaging